2017
DOI: 10.7150/thno.19900
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging

Abstract: Rationale The early detection of primary tumours and metastatic disease is vital for successful therapy and is contingent upon highly specific molecular markers and sensitive, non-invasive imaging techniques. We hypothesized that the accumulation of activated platelets within tumours is a general phenomenon and thus represents a novel means for the molecular imaging of cancer. Here we investigate a unique single chain antibody (scFv), which specifically targets activated platelets, as a novel biotechnological … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
45
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 49 publications
(47 citation statements)
references
References 28 publications
1
45
0
1
Order By: Relevance
“…Our in vitro and in vivo data show that netrin-1, although described as a secreted and diffusible protein, bound to the cell surface and/or extracellular matrix. This observation is in line with previous reports about USMI of secreted frizzled related protein 2, interleukin 16, and GPIIb/IIIa in tumors, and confirms the feasibility of USMI in settings where free-circulating proteins can potentially saturate MBs and prevent immobilization 22 , 48 , 49 . Inter- and intra-tumoral heterogeneity with regard to vascular perfusion rates and functionality of the vascular network are crucial factors for USMI with micrometer-sized contrast agents that are injected and limited to the blood vessels 50 , 51 .…”
Section: Discussionsupporting
confidence: 92%
“…Our in vitro and in vivo data show that netrin-1, although described as a secreted and diffusible protein, bound to the cell surface and/or extracellular matrix. This observation is in line with previous reports about USMI of secreted frizzled related protein 2, interleukin 16, and GPIIb/IIIa in tumors, and confirms the feasibility of USMI in settings where free-circulating proteins can potentially saturate MBs and prevent immobilization 22 , 48 , 49 . Inter- and intra-tumoral heterogeneity with regard to vascular perfusion rates and functionality of the vascular network are crucial factors for USMI with micrometer-sized contrast agents that are injected and limited to the blood vessels 50 , 51 .…”
Section: Discussionsupporting
confidence: 92%
“…Irrespective of the coupling tracer, this innovative approach allowed us to individuate activated platelets within the tumor microenvironment with high specificity, and sensitivity and give an accurate anatomical view of the tumor itself. The study was carried out in four different human tumor xenograft mouse models, including SKBr3 and MDA-MB-231 breast cancer, HT-1080 fibrosarcoma, and Ramos Burkitt’s lymphoma [ 130 ]. Further studies are needed using these GPIIb/IIIa-based contrast agents to confirm their possible use as an auxiliary non-invasive method for the detection and imaging of cancer and metastatic lesions.…”
Section: Effects Of Antiplatelet Agents In Cancermentioning
confidence: 99%
“…Addressing a major clinical need, we provide proof of concept of the therapeutic efficacy of our novel ADC in treating both primary tumor and preventing metastasis using a murine model of the difficult to treat triple negative breast cancer. Moreover, we have previously established the ability of the activated platelet-specific scFv for imaging a broad range of tumors 15 which raises the prospect of an integrated approach for cancer diagnosis and therapy, by utilizing molecular imaging as a means to detect tumor-associated platelets, and therefore predict those likely to respond to platelet-targeted therapy. Together, these findings demonstrate the broad potential of our unique activated platelet-targeting approach as a novel theranostic anti-cancer strategy, especially for cancers that do not express specific molecular epitopes suitable for therapeutic targeting.…”
Section: Discussionmentioning
confidence: 99%
“…In contrast, upon platelet activation, GPIIb/IIIa undergoes a confirmation change such that it adopts a high affinity conformation for ligand binding 14. Indeed, we recently provided proof of concept that the high affinity conformation of GPIIb/IIIa on activated platelets can serve as a molecular targeting epitope for the tumor microenvironment in several types of cancers in mice and humans 15. Therefore, targeting activated platelets in the tumor microenvironment, using a highly abundant and specific epitope, represents a novel approach for the targeted delivery of tumor directed chemotherapy.…”
Section: Introductionmentioning
confidence: 99%